Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

November 28, 2007 updated by: Abbott

A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients With Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab

The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are intolerant to infliximab, and to evaluate safety

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment

1000

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35209
    • Arkansas
      • Jonesboro, Arkansas, United States, 72401
      • Little Rock, Arkansas, United States, 72205
    • California
      • Roseville, California, United States, 95661
      • San Francisco, California, United States, 94115
    • Colorado
      • Englewood, Colorado, United States, 80113
      • Wheat Ridge, Colorado, United States, 80033
    • Connecticut
      • Bridgeport, Connecticut, United States, 06606
      • Hamden, Connecticut, United States, 06518
    • Florida
      • Clearwater, Florida, United States, 33765
      • Gainesville, Florida, United States, 32607
      • Gainesville, Florida, United States, 32610
      • Hollywood, Florida, United States, 33021
      • Jacksonville, Florida, United States, 32256
      • Jacksonville, Florida, United States, 32224
      • Miami, Florida, United States, 33173
      • North Miami Beach, Florida, United States, 33162
      • Winter Park, Florida, United States, 32789
    • Georgia
      • Atlanta, Georgia, United States, 30342
      • Atlanta, Georgia, United States, 30308
      • Atlanta, Georgia, United States, 30309
      • Conyers, Georgia, United States, 30012
      • Marietta, Georgia, United States, 30060
      • Savannah, Georgia, United States, 31405
    • Illinois
      • Arlington Heights, Illinois, United States, 60005
      • Moline, Illinois, United States, 61265
      • Rockford, Illinois, United States, 61107
    • Indiana
      • Columbus, Indiana, United States, 47201
      • Indianapolis, Indiana, United States, 46237
      • Indianapolis, Indiana, United States, 46202-5250
    • Iowa
      • Clive, Iowa, United States, 50325
      • Davenport, Iowa, United States, 52807
    • Kansas
      • Overland Park, Kansas, United States, 66212
      • Topeka, Kansas, United States, 66606
    • Kentucky
      • Lexington, Kentucky, United States, 40536
    • Maryland
      • Annapolis, Maryland, United States, 21401
      • Chevy Chase, Maryland, United States, 20815
      • Lutherville, Maryland, United States, 21093
      • Silver Spring, Maryland, United States, 20901
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
      • Boston, Massachusetts, United States, 02118
      • Burlington, Massachusetts, United States, 01805
    • Michigan
      • Troy, Michigan, United States, 48098
    • Minnesota
      • Plymouth, Minnesota, United States, 55446
    • Mississippi
      • Picayune, Mississippi, United States, 39466
    • Missouri
      • Kansas City, Missouri, United States, 64131
      • Mexico, Missouri, United States, 65265-3726
      • St. Louis, Missouri, United States, 63128
    • New Hampshire
      • Lebanon, New Hampshire, United States, 03756
    • New Jersey
      • Egg Harbor Township, New Jersey, United States, 08234
      • Glen Ridge, New Jersey, United States, 07028
      • Manalapan, New Jersey, United States, 07726
    • New York
      • Great Neck, New York, United States, 11021
      • Lake Success, New York, United States, 11042
      • New York, New York, United States, 10021
      • New York, New York, United States, 10022
      • New York, New York, United States, 10028
      • New York, New York, United States, 10128
      • Rochester, New York, United States, 14607
    • North Carolina
      • Charlotte, North Carolina, United States, 28207
      • Charlotte, North Carolina, United States, 28211
      • Jacksonville, North Carolina, United States, 28546
      • Rocky Mount, North Carolina, United States, 27804
      • Wilmington, North Carolina, United States, 28401
      • Wilmington, North Carolina, United States, 28403
    • Ohio
      • Beachwood, Ohio, United States, 44122
      • Cincinnati, Ohio, United States, 45220
      • Cincinnati, Ohio, United States, 45242
      • Cincinnati, Ohio, United States, 45219
      • Cleveland, Ohio, United States, 44195
      • Warren, Ohio, United States, 44484
    • Oklahoma
      • Tulsa, Oklahoma, United States, 74104
      • Tulsa, Oklahoma, United States, 74135
    • Oregon
      • Portland, Oregon, United States, 97225
      • Portland, Oregon, United States, 97220
    • Pennsylvania
      • Beaver Falls, Pennsylvania, United States, 15010
      • Duncansville, Pennsylvania, United States, 16635
      • Philadelphia, Pennsylvania, United States, 19107
      • Pittsburgh, Pennsylvania, United States, 15232
      • Pittsburgh, Pennsylvania, United States, 15224
      • Pittsburgh, Pennsylvania, United States, 15243
      • Sayre, Pennsylvania, United States, 18840
    • South Carolina
      • Columbia, South Carolina, United States, 29204
    • Tennessee
      • Chattanooga, Tennessee, United States, 37404
      • Chattanooga, Tennessee, United States, 37403
      • Germantown, Tennessee, United States, 38138
    • Texas
      • Austin, Texas, United States, 78745
    • Utah
      • South Ogden, Utah, United States, 84405
    • Virginia
      • Norfolk, Virginia, United States, 23502
    • Washington
      • Bellevue, Washington, United States, 98004
      • Seattle, Washington, United States, 98101
      • Spokane, Washington, United States, 99204
      • Vancouver, Washington, United States, 98664
    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53226
      • Milwaukee, Wisconsin, United States, 53233
      • Milwaukee, Wisconsin, United States, 53215
      • Monroe, Wisconsin, United States, 53566

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient diagnosed with moderate to severe Crohn's Disease.
  • Failed prior infliximab therapy.
  • Patient is judged to be in generally good health as determined by the principal investigator.

Exclusion Criteria:

  • Previous treatment with adalimumab.
  • Patient considered by the investigator, for any reason, to be an unsuitable candidate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
AEs, laboratory data, physical examinations and vital signs

Secondary Outcome Measures

Outcome Measure
Efficacy variables will be assessed from Outcomes Questionnaires

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2006

Study Completion (Actual)

May 1, 2007

Study Registration Dates

First Submitted

June 19, 2006

First Submitted That Met QC Criteria

June 19, 2006

First Posted (Estimate)

June 20, 2006

Study Record Updates

Last Update Posted (Estimate)

November 29, 2007

Last Update Submitted That Met QC Criteria

November 28, 2007

Last Verified

November 1, 2007

More Information

Terms related to this study

Other Study ID Numbers

  • M06-808
  • CHOICE

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.